Critical Clinical Evaluation of COVID-19 Patients with Tuberculosis in the Indian Sub-Continent

Author:

Selvaraj Hemalatha1ORCID,Damadarosamy Kumudha2,Kiruthiga Natarajan1,Rani K.Reeta Vijaya3,Duraisamy Kanagaraj4,Dhanasekaran Muralikrishnan5,Deruiter Jack5,Ren Jun67,Thangavel Sivakumar1,Parise Rachel5

Affiliation:

1. Department of Pharmacy Practice, Nandha College of Pharmacy, Tamilnadu, India

2. Department of Pharmaceutical Chemistry, Karpagam Academy of Higher Education, Tamil Nadu, India

3. Surya School of Pharmacy, Surya Group of Institutions, Tamil Nadu, India

4. Deputy Director of Medical Services, District TB Centre, Erode, Tamil Nadu, India

5. Department of Drug Discovery Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA

6. Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China

7. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA

Abstract

Background: COVID-19 and tuberculosis (TB) are infectious diseases that predominantly affect the respiratory system with common symptoms, such as cough, fever, and shortness of breath, making them dual burdens. Methods: This review will discuss the characteristics of the coexistence of TB and new infectious illnesses to provide a framework for addressing the current epidemic. Currently, there are no clear and significant data on COVID-19 infection in TB patients, they may not respond appropriately to drug therapy and may have worse treatment outcomes, especially if their TB treatment is interrupted. Due to emergence, measurements should be taken to minimize TB and COVID-19 transmission in communal settings and health care institutions were created. For both TB and COVID-19, accurate diagnostic testing and well-designed, and established therapeutic strategies are required for effective treatment. Results: Several health care organizations and networks have specimen transit methods that can be utilized to diagnose and monitor the etiology and progression of COVID 19 and perform contact tracing in developed and underdeveloped nations. Furthermore, patients and health care programs could benefit from increased use of digital health technology, which could improve communication, counseling, treatment, and information management, along with other capabilities to improve health care. Conclusions: Patients with COVID-19 pulmonary/respiratory problems may seek treatment from respiratory physicians, pulmonologists, TB experts, and even primary health care workers. To have prophylactic and therapeutic strategies against COVID-19, TB patients should take the appropriate health care measures recommended by health care professionals/government officials and maintain their TB therapy as indicated.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Pharmacology,Toxicology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3